Resection of primary lesion for patients with metastatic breast cancer: where are we now?

被引:6
|
作者
Hu, Qiancheng [1 ]
Zhong, Xiaorong [1 ,2 ,3 ]
Liu, Xu [2 ]
Xie, Yuxin [1 ,2 ]
Hu, Kejia [2 ]
He, Ping [1 ,3 ]
Lu, Donghao [1 ,3 ,4 ]
Zheng, Hong [1 ,2 ,3 ]
机构
[1] Sichuan Univ, West China Med Sch, West China Hosp, Dept Med Oncol,Canc Ctr, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Med Sch, West China Hosp,Natl Collaborat Innovat Ctr Bioth, State Key Lab Biotherapy,Lab Tumor Mol Diag, Chengdu 610041, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Clin Res Ctr Breast, Chengdu 610041, Sichuan, Peoples R China
[4] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
基金
中国国家自然科学基金;
关键词
Breast cancer; distant metastasis; resection of the primary lesion;
D O I
10.21037/cco.2018.05.03
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is largely unclear that whether or not surgical resection of the primary tumors could confer survival benefit among patients with metastatic breast cancer at initial presentation. We thoroughly reviewed the up-to-date evidence on surgical resection of the primary lesion in metastatic breast cancer, including comparative studies (of particular interest in risk modifiers, the type, and timing of surgical procedures), Chinese and international guidelines, as well as the progress of clinical trials. Partial modified radical mastectomy and breast-conserving surgery are by far the most common choices for patients with metastatic breast cancer. Patients with certain characteristics, for example, younger than 45 years of age or with oligometastasis, might benefit from the surgery. The type and timing of surgical procedures are still in debate according to the guidelines from different countries. Forthcoming evidence from the ongoing clinical trials might help close the knowledge gaps in surgical treatment for patients with metastatic breast cancer and aid the decision-making in clinical practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading
    Jeremy Force
    Jorge Henrique Santos Leal
    Heather L. McArthur
    Current Treatment Options in Oncology, 2019, 20
  • [32] Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go
    Buchsbaum, Rachel J.
    Oh, Sun Young
    CANCERS, 2016, 8 (02)
  • [33] Surgical Resection of the Primary Tumor, Chest Wall Control, and Survival in Women With Metastatic Breast Cancer
    Hazard, Hannah W.
    Gorla, Seema R.
    Scholtens, Denise
    Kiel, Krystyna
    Gradishar, William J.
    Khan, Seema A.
    CANCER, 2008, 113 (08) : 2011 - 2019
  • [34] Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients
    Shoji, Fumihiro
    Yamashita, Nami
    Inoue, Yuka
    Kozuma, Yuka
    Toyokawa, Gouji
    Hirai, Fumihiko
    Ito, Kensaku
    Tagawa, Tetsuzo
    Okamoto, Tatsuro
    Maehara, Yoshihiko
    ANTICANCER RESEARCH, 2017, 37 (10) : 5871 - 5876
  • [35] Steroid metabolism in breast cancer: Where are we and what are we missing?
    Africander, Donita
    Storbeck, Karl-Heinz
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2018, 466 : 86 - 97
  • [36] Breast cancer pharmacogenomics: where we are going FOREWORD
    Newman, William G.
    Flockhart, Dave
    PHARMACOGENOMICS, 2012, 13 (06) : 629 - 631
  • [37] Expression of CXCR4 in the Primary Lesion of Recurrent Metastatic Breast Cancer and Its Association With Prognosis
    Huang, Danchan
    Lin, Danxia
    Liang, Sixian
    Lin, Jing
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2025, 18 : 1543 - 1553
  • [38] Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?
    Nicole Williams
    Michael Grimm
    Kelly Gast
    Maryam Lustberg
    Current Breast Cancer Reports, 2022, 14 : 142 - 152
  • [39] Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?
    Williams, Nicole
    Grimm, Michael
    Gast, Kelly
    Lustberg, Maryam
    CURRENT BREAST CANCER REPORTS, 2022, 14 (04) : 142 - 152
  • [40] Hyaluronic Acid-Based Nanomaterials Applied to Cancer: Where Are We Now?
    Machado, Vera
    Morais, Mariana
    Medeiros, Rui
    PHARMACEUTICS, 2022, 14 (10)